Hatchtech Pty Ltd. is the developer of a proprietary next generation head lice treatment, DeOvo™, which has just successfully completed a Phase IIb clinical trial and is poised to enter Phase III. DeOvo™ is a head lice product that kills both lice and eggs and treats all life cycle stages of the organism in a single application.

Other head lice treatments do not target the eggs so that repeat applications are needed to completely eliminate an infestation. In addition, while head lice worldwide have developed resistance to many of the available products there is no known cross resistance with DeOvo™ as it has a totally novel mode of action. DeOvo™ is a cosmetically elegant topical lotion containing an inhibitor of metalloproteases known to impede all stages of the louse lifecycle from egg to adult. A substantial body of scientific data has established the mode of action and preclinical and clinical studies have shown DeOvo™ to be both highly effective and safe.

Hatchtech is securely financed by a consortium of specialist venture capitalists and is co-located in New Jersey, USA and Melbourne, Australia.